{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:35:14Z","timestamp":1790811314113,"version":"4.1.0"},"reference-count":111,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000361","name":"Diabetes UK","doi-asserted-by":"publisher","award":["23\/0006598"],"award-info":[{"award-number":["23\/0006598"]}],"id":[{"id":"10.13039\/501100000361","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s00125-026-06759-6","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T13:05:13Z","timestamp":1780923913000},"page":"3105-3120","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Genetics of MASLD: a diabetes perspective"],"prefix":"10.1007","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4665-3886","authenticated-orcid":false,"given":"Josh","family":"Bilson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9672-9477","authenticated-orcid":false,"given":"Hanieh","family":"Yaghootkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"issue":"10","key":"6759_CR1","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1016\/j.cgh.2024.03.006","volume":"22","author":"ZM Younossi","year":"2024","unstructured":"Younossi ZM, Golabi P, Price JK et al (2024) The global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among patients with type 2 diabetes. Clin Gastroenterol Hepatol 22(10):1999-2010.e1998. https:\/\/doi.org\/10.1016\/j.cgh.2024.03.006","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"6759_CR2","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1136\/gutjnl-2023-330595","volume":"73","author":"G Targher","year":"2024","unstructured":"Targher G, Byrne CD, Tilg H (2024) MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut 73(4):691\u2013702. https:\/\/doi.org\/10.1136\/gutjnl-2023-330595","journal-title":"Gut"},{"issue":"6","key":"6759_CR3","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/hep.0000000000000520","volume":"78","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V et al (2023) A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 78(6):1966\u20131986. https:\/\/doi.org\/10.1097\/hep.0000000000000520","journal-title":"Hepatology"},{"issue":"2","key":"6759_CR4","doi-asserted-by":"publisher","first-page":"e76","DOI":"10.1016\/j.jhep.2023.08.026","volume":"80","author":"H Hagstr\u00f6m","year":"2024","unstructured":"Hagstr\u00f6m H, Vessby J, Ekstedt M, Shang Y (2024) 99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical. J Hepatol 80(2):e76\u2013e77. https:\/\/doi.org\/10.1016\/j.jhep.2023.08.026","journal-title":"J Hepatol"},{"issue":"6","key":"6759_CR5","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.jhep.2024.06.030","volume":"81","author":"A Ahmed","year":"2024","unstructured":"Ahmed A, Cule M, Bell JD, Sattar N, Yaghootkar H (2024) Differing genetic variants associated with liver fat and their contrasting relationships with cardiovascular diseases and cancer. J Hepatol 81(6):921\u2013929. https:\/\/doi.org\/10.1016\/j.jhep.2024.06.030","journal-title":"J Hepatol"},{"issue":"12","key":"6759_CR6","doi-asserted-by":"publisher","first-page":"3614","DOI":"10.1038\/s41591-024-03284-0","volume":"30","author":"O Jamialahmadi","year":"2024","unstructured":"Jamialahmadi O, De Vincentis A, Tavaglione F et al (2024) Partitioned polygenic risk scores identify distinct types of metabolic dysfunction-associated steatotic liver disease. Nat Med 30(12):3614\u20133623. https:\/\/doi.org\/10.1038\/s41591-024-03284-0","journal-title":"Nat Med"},{"issue":"8","key":"6759_CR7","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1111\/j.1478-3231.2012.02823.x","volume":"32","author":"AD Tarnoki","year":"2012","unstructured":"Tarnoki AD, Tarnoki DL, Bata P et al (2012) Heritability of non-alcoholic fatty liver disease and association with abnormal vascular parameters: a twin study. Liver Int 32(8):1287\u20131293. https:\/\/doi.org\/10.1111\/j.1478-3231.2012.02823.x","journal-title":"Liver Int"},{"issue":"7","key":"6759_CR8","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1053\/j.gastro.2015.08.011","volume":"149","author":"R Loomba","year":"2015","unstructured":"Loomba R, Schork N, Chen CH et al (2015) Heritability of hepatic fibrosis and steatosis based on a prospective twin study. Gastroenterology 149(7):1784\u20131793. https:\/\/doi.org\/10.1053\/j.gastro.2015.08.011","journal-title":"Gastroenterology"},{"issue":"5","key":"6759_CR9","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1053\/j.gastro.2009.01.050","volume":"136","author":"JB Schwimmer","year":"2009","unstructured":"Schwimmer JB, Celedon MA, Lavine JE et al (2009) Heritability of nonalcoholic fatty liver disease. Gastroenterology 136(5):1585\u20131592. https:\/\/doi.org\/10.1053\/j.gastro.2009.01.050","journal-title":"Gastroenterology"},{"issue":"7","key":"6759_CR10","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1172\/jci93465","volume":"127","author":"C Caussy","year":"2017","unstructured":"Caussy C, Soni M, Cui J et al (2017) Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis. J Clin Invest 127(7):2697\u20132704. https:\/\/doi.org\/10.1172\/jci93465","journal-title":"J Clin Invest"},{"issue":"21","key":"6759_CR11","doi-asserted-by":"publisher","first-page":"e162513","DOI":"10.1172\/jci162513","volume":"132","author":"N Tamaki","year":"2022","unstructured":"Tamaki N, Ahlholm N, Luukkonen PK et al (2022) Risk of advanced fibrosis in first-degree relatives of patients with nonalcoholic fatty liver disease. J Clin Invest 132(21):e162513. https:\/\/doi.org\/10.1172\/jci162513","journal-title":"J Clin Invest"},{"issue":"6","key":"6759_CR12","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/j.jhep.2023.08.018","volume":"79","author":"F Ebrahimi","year":"2023","unstructured":"Ebrahimi F, Hagstr\u00f6m H, Sun J et al (2023) Familial coaggregation of MASLD with hepatocellular carcinoma and adverse liver outcomes: nationwide multigenerational cohort study. J Hepatol 79(6):1374\u20131384. https:\/\/doi.org\/10.1016\/j.jhep.2023.08.018","journal-title":"J Hepatol"},{"issue":"3","key":"6759_CR13","doi-asserted-by":"publisher","first-page":"e1001324","DOI":"10.1371\/journal.pgen.1001324","volume":"7","author":"EK Speliotes","year":"2011","unstructured":"Speliotes EK, Yerges-Armstrong LM, Wu J et al (2011) Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet 7(3):e1001324. https:\/\/doi.org\/10.1371\/journal.pgen.1001324","journal-title":"PLoS Genet"},{"issue":"1","key":"6759_CR14","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s12916-019-1364-z","volume":"17","author":"B Namjou","year":"2019","unstructured":"Namjou B, Lingren T, Huang Y et al (2019) GWAS and enrichment analyses of non-alcoholic fatty liver disease identify new trait-associated genes and pathways across eMERGE Network. BMC Med 17(1):135. https:\/\/doi.org\/10.1186\/s12916-019-1364-z","journal-title":"BMC Med"},{"issue":"12","key":"6759_CR15","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/ng.257","volume":"40","author":"S Romeo","year":"2008","unstructured":"Romeo S, Kozlitina J, Xing C et al (2008) Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 40(12):1461\u20131465. https:\/\/doi.org\/10.1038\/ng.257","journal-title":"Nat Genet"},{"issue":"12","key":"6759_CR16","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1056\/NEJMoa1712191","volume":"378","author":"NS Abul-Husn","year":"2018","unstructured":"Abul-Husn NS, Cheng X, Li AH et al (2018) A protein-truncating HSD17B13 variant and protection from chronic liver disease. N Engl J Med 378(12):1096\u20131106. https:\/\/doi.org\/10.1056\/NEJMoa1712191","journal-title":"N Engl J Med"},{"issue":"7","key":"6759_CR17","doi-asserted-by":"publisher","first-page":"e186424","DOI":"10.1172\/jci186424","volume":"135","author":"VL Chen","year":"2025","unstructured":"Chen VL, Kuppa A, Oliveri A et al (2025) Human genetics of metabolic dysfunction-associated steatotic liver disease: from variants to cause to precision treatment. J Clin Invest 135(7):e186424. https:\/\/doi.org\/10.1172\/jci186424","journal-title":"J Clin Invest"},{"issue":"4","key":"6759_CR18","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/ng.2901","volume":"46","author":"J Kozlitina","year":"2014","unstructured":"Kozlitina J, Smagris E, Stender S et al (2014) Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 46(4):352\u2013356. https:\/\/doi.org\/10.1038\/ng.2901","journal-title":"Nat Genet"},{"issue":"12","key":"6759_CR19","doi-asserted-by":"publisher","first-page":"100855","DOI":"10.1016\/j.xcrm.2022.100855","volume":"3","author":"J Park","year":"2022","unstructured":"Park J, MacLean MT, Lucas AM et al (2022) Exome-wide association analysis of CT imaging-derived hepatic fat in a medical biobank. Cell Rep Med 3(12):100855. https:\/\/doi.org\/10.1016\/j.xcrm.2022.100855","journal-title":"Cell Rep Med"},{"issue":"2","key":"6759_CR20","doi-asserted-by":"publisher","first-page":"qzae031","DOI":"10.1093\/gpbjnl\/qzae031","volume":"22","author":"Y Li","year":"2024","unstructured":"Li Y, van den Berg EH, Kurilshikov A et al (2024) Genome-wide studies reveal genetic risk factors for hepatic fat content. Genomics Proteomics Bioinformatics 22(2):qzae031. https:\/\/doi.org\/10.1093\/gpbjnl\/qzae031","journal-title":"Genomics Proteomics Bioinformatics"},{"issue":"10","key":"6759_CR21","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1038\/s41588-023-01497-6","volume":"55","author":"Y Chen","year":"2023","unstructured":"Chen Y, Du X, Kuppa A et al (2023) Genome-wide association meta-analysis identifies 17 loci associated with nonalcoholic fatty liver disease. Nat Genet 55(10):1640\u20131650. https:\/\/doi.org\/10.1038\/s41588-023-01497-6","journal-title":"Nat Genet"},{"issue":"2","key":"6759_CR22","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.jhep.2020.03.032","volume":"73","author":"CA Parisinos","year":"2020","unstructured":"Parisinos CA, Wilman HR, Thomas EL et al (2020) Genome-wide and Mendelian randomisation studies of liver MRI yield insights into the pathogenesis of steatohepatitis. J Hepatol 73(2):241\u2013251. https:\/\/doi.org\/10.1016\/j.jhep.2020.03.032","journal-title":"J Hepatol"},{"issue":"2","key":"6759_CR23","doi-asserted-by":"publisher","first-page":"460","DOI":"10.2337\/dc21-1262","volume":"45","author":"S Martin","year":"2022","unstructured":"Martin S, Sorokin EP, Thomas EL et al (2022) Estimating the effect of liver and pancreas volume and fat content on risk of diabetes: a Mendelian randomization study. Diabetes Care 45(2):460\u2013468. https:\/\/doi.org\/10.2337\/dc21-1262","journal-title":"Diabetes Care"},{"key":"6759_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s40246-026-00913-2","author":"D Meena","year":"2026","unstructured":"Meena D, Pansini M, Fichera A et al (2026) Unravelling genetic susceptibility and causal factors in liver health using MRI quantification of inflammation, fat and iron in the liver. Hum Genomics. https:\/\/doi.org\/10.1186\/s40246-026-00913-2","journal-title":"Hum Genomics"},{"issue":"3","key":"6759_CR25","doi-asserted-by":"publisher","first-page":"100066","DOI":"10.1016\/j.xgen.2021.100066","volume":"1","author":"ME Haas","year":"2021","unstructured":"Haas ME, Pirruccello JP, Friedman SN et al (2021) Machine learning enables new insights into genetic contributions to liver fat accumulation. Cell Genom 1(3):100066. https:\/\/doi.org\/10.1016\/j.xgen.2021.100066","journal-title":"Cell Genom"},{"issue":"3","key":"6759_CR26","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.jhep.2022.03.031","volume":"77","author":"GA Baselli","year":"2022","unstructured":"Baselli GA, Jamialahmadi O, Pelusi S et al (2022) Rare ATG7 genetic variants predispose patients to severe fatty liver disease. J Hepatol 77(3):596\u2013606. https:\/\/doi.org\/10.1016\/j.jhep.2022.03.031","journal-title":"J Hepatol"},{"issue":"1","key":"6759_CR27","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s12944-017-0570-y","volume":"16","author":"S Boonvisut","year":"2017","unstructured":"Boonvisut S, Yoshida K, Nakayama K, Watanabe K, Miyashita H, Iwamoto S (2017) Identification of deleterious rare variants in MTTP, PNPLA3, and TM6SF2 in Japanese males and association studies with NAFLD. Lipids Health Dis 16(1):183. https:\/\/doi.org\/10.1186\/s12944-017-0570-y","journal-title":"Lipids Health Dis"},{"issue":"8","key":"6759_CR28","doi-asserted-by":"publisher","first-page":"100764","DOI":"10.1016\/j.jhepr.2023.100764","volume":"5","author":"JI Grove","year":"2023","unstructured":"Grove JI, Lo PCK, Shrine N et al (2023) Identification and characterisation of a rare MTTP variant underlying hereditary non-alcoholic fatty liver disease. JHEP Rep 5(8):100764. https:\/\/doi.org\/10.1016\/j.jhepr.2023.100764","journal-title":"JHEP Rep"},{"issue":"11","key":"6759_CR29","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1038\/ng.970","volume":"43","author":"JC Chambers","year":"2011","unstructured":"Chambers JC, Zhang W, Sehmi J et al (2011) Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma. Nat Genet 43(11):1131\u20131138. https:\/\/doi.org\/10.1038\/ng.970","journal-title":"Nat Genet"},{"issue":"1","key":"6759_CR30","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/s41467-020-20870-1","volume":"12","author":"VL Chen","year":"2021","unstructured":"Chen VL, Du X, Chen Y et al (2021) Genome-wide association study of serum liver enzymes implicates diverse metabolic and liver pathology. Nat Commun 12(1):816. https:\/\/doi.org\/10.1038\/s41467-020-20870-1","journal-title":"Nat Commun"},{"issue":"6","key":"6759_CR31","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/s41588-022-01078-z","volume":"54","author":"M Vujkovic","year":"2022","unstructured":"Vujkovic M, Ramdas S, Lorenz KM et al (2022) A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation. Nat Genet 54(6):761\u2013771. https:\/\/doi.org\/10.1038\/s41588-022-01078-z","journal-title":"Nat Genet"},{"issue":"3","key":"6759_CR32","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jhep.2020.04.003","volume":"73","author":"QM Anstee","year":"2020","unstructured":"Anstee QM, Darlay R, Cockell S et al (2020) Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort(\u2606). J Hepatol 73(3):505\u2013515. https:\/\/doi.org\/10.1016\/j.jhep.2020.04.003","journal-title":"J Hepatol"},{"issue":"1","key":"6759_CR33","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1186\/s12864-025-11668-w","volume":"26","author":"R Li","year":"2025","unstructured":"Li R, Su K, Wu T et al (2025) Genome-wide enhancer-gene regulatory maps of liver reveal novel regulatory mechanisms underlying NAFLD pathogenesis. BMC Genomics 26(1):493. https:\/\/doi.org\/10.1186\/s12864-025-11668-w","journal-title":"BMC Genomics"},{"issue":"2","key":"6759_CR34","doi-asserted-by":"publisher","first-page":"100275","DOI":"10.1016\/j.xhgg.2024.100275","volume":"5","author":"GK Pandey","year":"2024","unstructured":"Pandey GK, Vadlamudi S, Currin KW et al (2024) Liver regulatory mechanisms of noncoding variants at lipid and metabolic trait loci. HGG Adv 5(2):100275. https:\/\/doi.org\/10.1016\/j.xhgg.2024.100275","journal-title":"HGG Adv"},{"issue":"4","key":"6759_CR35","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1093\/hmg\/ddae184","volume":"34","author":"Z Liu","year":"2025","unstructured":"Liu Z, Chen X, Yuan H, Jin L, Zhang T, Chen X (2025) Dissecting the shared genetic architecture between nonalcoholic fatty liver disease and type 2 diabetes. Hum Mol Genet 34(4):338\u2013346. https:\/\/doi.org\/10.1093\/hmg\/ddae184","journal-title":"Hum Mol Genet"},{"issue":"1","key":"6759_CR36","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1038\/s42003-022-04237-4","volume":"5","author":"D van der Meer","year":"2022","unstructured":"van der Meer D, Gurholt TP, S\u00f8nderby IE et al (2022) The link between liver fat and cardiometabolic diseases is highlighted by genome-wide association study of MRI-derived measures of body composition. Commun Biol 5(1):1271. https:\/\/doi.org\/10.1038\/s42003-022-04237-4","journal-title":"Commun Biol"},{"issue":"11","key":"6759_CR37","doi-asserted-by":"publisher","first-page":"100437","DOI":"10.1016\/j.xcrm.2021.100437","volume":"2","author":"N Ghodsian","year":"2021","unstructured":"Ghodsian N, Abner E, Emdin CA et al (2021) Electronic health record-based genome-wide meta-analysis provides insights on the genetic architecture of non-alcoholic fatty liver disease. Cell Rep Med 2(11):100437. https:\/\/doi.org\/10.1016\/j.xcrm.2021.100437","journal-title":"Cell Rep Med"},{"issue":"2","key":"6759_CR38","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/s2213-8587(24)00318-8","volume":"13","author":"N Stefan","year":"2025","unstructured":"Stefan N, Yki-J\u00e4rvinen H, Neuschwander-Tetri BA (2025) Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment. Lancet Diabetes Endocrinol 13(2):134\u2013148. https:\/\/doi.org\/10.1016\/s2213-8587(24)00318-8","journal-title":"Lancet Diabetes Endocrinol"},{"key":"6759_CR39","doi-asserted-by":"publisher","first-page":"156552","DOI":"10.1016\/j.metabol.2026.156552","volume":"178","author":"NN Atabaki","year":"2026","unstructured":"Atabaki NN, Coral DE, Pomares-Millan H et al (2026) A biological-systems-based analysis using proteomic and metabolic network inference reveals mechanistic insights into hepatic steatosis. Metabolism 178:156552. https:\/\/doi.org\/10.1016\/j.metabol.2026.156552","journal-title":"Metabolism"},{"issue":"12","key":"6759_CR40","doi-asserted-by":"publisher","first-page":"4369","DOI":"10.2337\/db14-0318","volume":"63","author":"H Yaghootkar","year":"2014","unstructured":"Yaghootkar H, Scott RA, White CC et al (2014) Genetic evidence for a normal-weight \u201cmetabolically obese\u201d phenotype linking insulin resistance, hypertension, coronary artery disease, and type 2 diabetes. Diabetes 63(12):4369\u20134377. https:\/\/doi.org\/10.2337\/db14-0318","journal-title":"Diabetes"},{"issue":"8","key":"6759_CR41","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.2337\/db21-0129","volume":"70","author":"S Martin","year":"2021","unstructured":"Martin S, Cule M, Basty N et al (2021) Genetic evidence for different adiposity phenotypes and their opposing influences on ectopic fat and risk of cardiometabolic disease. Diabetes 70(8):1843\u20131856. https:\/\/doi.org\/10.2337\/db21-0129","journal-title":"Diabetes"},{"issue":"6","key":"6759_CR42","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.2337\/db23-1005","volume":"73","author":"A Abraham","year":"2024","unstructured":"Abraham A, Cule M, Thanaj M et al (2024) Genetic evidence for distinct biological mechanisms that link adiposity to type 2 diabetes: toward precision medicine. Diabetes 73(6):1012\u20131025. https:\/\/doi.org\/10.2337\/db23-1005","journal-title":"Diabetes"},{"issue":"1","key":"6759_CR43","doi-asserted-by":"publisher","first-page":"207","DOI":"10.2337\/db18-0708","volume":"68","author":"Y Ji","year":"2019","unstructured":"Ji Y, Yiorkas AM, Frau F et al (2019) Genome-wide and abdominal MRI data provide evidence that a genetically determined favorable adiposity phenotype is characterized by lower ectopic liver fat and lower risk of type 2 diabetes, heart disease, and hypertension. Diabetes 68(1):207\u2013219. https:\/\/doi.org\/10.2337\/db18-0708","journal-title":"Diabetes"},{"issue":"7","key":"6759_CR44","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.2337\/db24-1103","volume":"74","author":"CS Odoemelam","year":"2025","unstructured":"Odoemelam CS, Naz A, Thanaj M et al (2025) Identifying four obesity axes through integrative multiomics and imaging analysis. Diabetes 74(7):1168\u20131183. https:\/\/doi.org\/10.2337\/db24-1103","journal-title":"Diabetes"},{"issue":"12","key":"6759_CR45","doi-asserted-by":"publisher","first-page":"4180","DOI":"10.1038\/s41591-025-03976-1","volume":"31","author":"S Zorn","year":"2025","unstructured":"Zorn S, Bounds R, Williamson A et al (2025) Obesity due to MC4R deficiency is associated with reduced cholesterol, triglycerides and cardiovascular disease risk. Nat Med 31(12):4180\u20134188. https:\/\/doi.org\/10.1038\/s41591-025-03976-1","journal-title":"Nat Med"},{"key":"6759_CR46","doi-asserted-by":"publisher","first-page":"7792701","DOI":"10.1155\/jobe\/7792701","volume":"2025","author":"A Ahmed","year":"2025","unstructured":"Ahmed A, Cule M, Naz A et al (2025) MRI-based genetic studies reveal specific genetic variants and disease risks associated with fat distribution across anatomical sites. J Obes 2025:7792701. https:\/\/doi.org\/10.1155\/jobe\/7792701","journal-title":"J Obes"},{"issue":"12","key":"6759_CR47","doi-asserted-by":"publisher","first-page":"3624","DOI":"10.1038\/s41591-024-03283-1","volume":"30","author":"V Raverdy","year":"2024","unstructured":"Raverdy V, Tavaglione F, Chatelain E et al (2024) Data-driven cluster analysis identifies distinct types of metabolic dysfunction-associated steatotic liver disease. Nat Med 30(12):3624\u20133633. https:\/\/doi.org\/10.1038\/s41591-024-03283-1","journal-title":"Nat Med"},{"issue":"7","key":"6759_CR48","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1002\/hep4.1353","volume":"3","author":"L Barata","year":"2019","unstructured":"Barata L, Feitosa MF, Bielak LF et al (2019) Insulin resistance exacerbates genetic predisposition to nonalcoholic fatty liver disease in individuals without diabetes. Hepatol Commun 3(7):894\u2013907. https:\/\/doi.org\/10.1002\/hep4.1353","journal-title":"Hepatol Commun"},{"issue":"3","key":"6759_CR49","doi-asserted-by":"publisher","first-page":"e16106","DOI":"10.1111\/liv.16106","volume":"45","author":"EK Speliotes","year":"2025","unstructured":"Speliotes EK, Schneider CV (2025) PNPLA3 I148M interacts with environmental triggers to cause human disease. Liver Int 45(3):e16106. https:\/\/doi.org\/10.1111\/liv.16106","journal-title":"Liver Int"},{"issue":"5","key":"6759_CR50","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1097\/hep.0000000000000896","volume":"80","author":"N Chalasani","year":"2024","unstructured":"Chalasani N, Vilar-Gomez E, Loomba R et al (2024) PNPLA3 rs738409, age, diabetes, sex, and advanced fibrosis jointly contribute to the risk of major adverse liver outcomes in metabolic dysfunction-associated steatotic liver disease. Hepatology 80(5):1212\u20131226. https:\/\/doi.org\/10.1097\/hep.0000000000000896","journal-title":"Hepatology"},{"issue":"5","key":"6759_CR51","doi-asserted-by":"publisher","first-page":"994","DOI":"10.14309\/ajg.0000000000001072","volume":"116","author":"E Vilar-Gomez","year":"2021","unstructured":"Vilar-Gomez E, Pirola CJ, Sookoian S et al (2021) Impact of the association between PNPLA3 genetic variation and dietary intake on the risk of significant fibrosis in patients with NAFLD. Am J Gastroenterol 116(5):994\u20131006. https:\/\/doi.org\/10.14309\/ajg.0000000000001072","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"6759_CR52","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1111\/liv.15588","volume":"43","author":"X Ge","year":"2023","unstructured":"Ge X, Wang X, Yan Y et al (2023) Behavioural activity pattern, genetic factors, and the risk of nonalcoholic fatty liver disease: a prospective study in the UK Biobank. Liver Int 43(6):1287\u20131297. https:\/\/doi.org\/10.1111\/liv.15588","journal-title":"Liver Int"},{"issue":"3","key":"6759_CR53","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1007\/s12263-014-0392-8","volume":"9","author":"V Nobili","year":"2014","unstructured":"Nobili V, Liccardo D, Bedogni G et al (2014) Influence of dietary pattern, physical activity, and I148M PNPLA3 on steatosis severity in at-risk adolescents. Genes Nutr 9(3):392. https:\/\/doi.org\/10.1007\/s12263-014-0392-8","journal-title":"Genes Nutr"},{"issue":"5","key":"6759_CR54","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/s41430-024-01416-w","volume":"78","author":"MR Alvares-da-Silva","year":"2024","unstructured":"Alvares-da-Silva MR, Ivancovsky-Wajcman D, Oliveira CP et al (2024) High red meat consumption among PNPLA3 polymorphism carriers is associated with NAFLD in a multi-center cross-sectional study. Eur J Clin Nutr 78(5):442\u2013448. https:\/\/doi.org\/10.1038\/s41430-024-01416-w","journal-title":"Eur J Clin Nutr"},{"issue":"6","key":"6759_CR55","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.3945\/ajcn.2010.30185","volume":"92","author":"JN Davis","year":"2010","unstructured":"Davis JN, L\u00ea KA, Walker RW et al (2010) Increased hepatic fat in overweight Hispanic youth influenced by interaction between genetic variation in PNPLA3 and high dietary carbohydrate and sugar consumption. Am J Clin Nutr 92(6):1522\u20131527. https:\/\/doi.org\/10.3945\/ajcn.2010.30185","journal-title":"Am J Clin Nutr"},{"issue":"4","key":"6759_CR56","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.jhep.2024.09.043","volume":"82","author":"E Vilar-Gomez","year":"2025","unstructured":"Vilar-Gomez E, Gawrieh S, Vuppalanchi R et al (2025) PNPLA3 rs738409, environmental factors and liver-related mortality in the US population. J Hepatol 82(4):571\u2013581. https:\/\/doi.org\/10.1016\/j.jhep.2024.09.043","journal-title":"J Hepatol"},{"issue":"R1","key":"6759_CR57","doi-asserted-by":"publisher","first-page":"R89","DOI":"10.1093\/hmg\/ddu328","volume":"23","author":"G Davey Smith","year":"2014","unstructured":"Davey Smith G, Hemani G (2014) Mendelian randomization: genetic anchors for causal inference in epidemiological studies. Hum Mol Genet 23(R1):R89-98. https:\/\/doi.org\/10.1093\/hmg\/ddu328","journal-title":"Hum Mol Genet"},{"issue":"2","key":"6759_CR58","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jhep.2020.03.006","volume":"73","author":"Z Liu","year":"2020","unstructured":"Liu Z, Zhang Y, Graham S et al (2020) Causal relationships between NAFLD, T2D and obesity have implications for disease subphenotyping. J Hepatol 73(2):263\u2013276. https:\/\/doi.org\/10.1016\/j.jhep.2020.03.006","journal-title":"J Hepatol"},{"issue":"8","key":"6759_CR59","doi-asserted-by":"publisher","first-page":"E1125","DOI":"10.1210\/jc.2015-1587","volume":"100","author":"N Santoro","year":"2015","unstructured":"Santoro N, Caprio S, Pierpont B, Van Name M, Savoye M, Parks EJ (2015) Hepatic de novo lipogenesis in obese youth is modulated by a common variant in the GCKR gene. J Clin Endocrinol Metab 100(8):E1125-1132. https:\/\/doi.org\/10.1210\/jc.2015-1587","journal-title":"J Clin Endocrinol Metab"},{"key":"6759_CR60","doi-asserted-by":"publisher","first-page":"110993","DOI":"10.1016\/j.diabres.2023.110993","volume":"206","author":"X Ni","year":"2023","unstructured":"Ni X, Tong C, Halengbieke A et al (2023) Association between nonalcoholic fatty liver disease and type 2 diabetes: a bidirectional two-sample mendelian randomization study. Diabetes Res Clin Pract 206:110993. https:\/\/doi.org\/10.1016\/j.diabres.2023.110993","journal-title":"Diabetes Res Clin Pract"},{"issue":"6","key":"6759_CR61","doi-asserted-by":"publisher","first-page":"103976","DOI":"10.1016\/j.numecd.2025.103976","volume":"35","author":"R Li","year":"2025","unstructured":"Li R, Wang T, Luo H, Fan Y, Guan Y, Tian Y (2025) Causal effects and mediating pathways of metabolic dysfunction-associated fatty liver disease on novel subtypes of adult-onset diabetes: a two-step Mendelian randomization study. Nutr Metab Cardiovasc Dis 35(6):103976. https:\/\/doi.org\/10.1016\/j.numecd.2025.103976","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"4","key":"6759_CR62","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1111\/liv.15845","volume":"44","author":"NC Lavrado","year":"2024","unstructured":"Lavrado NC, Salles GF, Cardoso CRL et al (2024) Impact of PNPLA3 and TM6SF2 polymorphisms on the prognosis of patients with MASLD and type 2 diabetes mellitus. Liver Int 44(4):1042\u20131050. https:\/\/doi.org\/10.1111\/liv.15845","journal-title":"Liver Int"},{"issue":"2","key":"6759_CR63","doi-asserted-by":"publisher","first-page":"101713","DOI":"10.1016\/j.jhepr.2025.101713","volume":"8","author":"DY Kim","year":"2026","unstructured":"Kim DY, Zhang HS, Lee JS et al (2026) Integration of PNPLA3 and TM6SF2 genotypes provides incremental improvement in advanced fibrosis prediction among MASLD patients with type 2 diabetes mellitus. JHEP Rep 8(2):101713. https:\/\/doi.org\/10.1016\/j.jhepr.2025.101713","journal-title":"JHEP Rep"},{"issue":"7","key":"6759_CR64","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.14309\/ajg.0000000000003169","volume":"120","author":"VL Chen","year":"2024","unstructured":"Chen VL, Oliveri A, Raut C, Chen Y, Cushing-Damm KC, Speliotes EK (2024) TM6SF2 -rs58542926 genotype has opposing effects on incidence of hepatic and cardiac events in a community cohort. Am J Gastroenterol 120(7):1538\u20131547. https:\/\/doi.org\/10.14309\/ajg.0000000000003169","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"6759_CR65","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/joim.12719","volume":"283","author":"P Dongiovanni","year":"2018","unstructured":"Dongiovanni P, Stender S, Pietrelli A et al (2018) Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver. J Intern Med 283(4):356\u2013370. https:\/\/doi.org\/10.1111\/joim.12719","journal-title":"J Intern Med"},{"issue":"1","key":"6759_CR66","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3390\/genes16010033","volume":"16","author":"P Giardoglou","year":"2024","unstructured":"Giardoglou P, Gavra I, Amanatidou AI et al (2024) Development of a polygenic risk score for metabolic dysfunction-associated steatotic liver disease prediction in UK biobank. Genes (Basel) 16(1):33. https:\/\/doi.org\/10.3390\/genes16010033","journal-title":"Genes (Basel)"},{"issue":"3","key":"6759_CR67","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.cgh.2021.05.056","volume":"20","author":"A De Vincentis","year":"2022","unstructured":"De Vincentis A, Tavaglione F, Jamialahmadi O et al (2022) A polygenic risk score to refine risk stratification and prediction for severe liver disease by clinical fibrosis scores. Clin Gastroenterol Hepatol 20(3):658\u2013673. https:\/\/doi.org\/10.1016\/j.cgh.2021.05.056","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"6759_CR68","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/s42255-025-01215-y","volume":"7","author":"X Zhang","year":"2025","unstructured":"Zhang X, Lau HC, Ha S et al (2025) Author Correction: intestinal TM6SF2 protects against metabolic dysfunction-associated steatohepatitis through the gut-liver axis. Nat Metab 7(1):230. https:\/\/doi.org\/10.1038\/s42255-025-01215-y","journal-title":"Nat Metab"},{"key":"6759_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.09.013","author":"E Vilar-Gomez","year":"2025","unstructured":"Vilar-Gomez E, Yates KP, Kleiner DE et al (2025) Genetic and non-genetic drivers of histological progression and regression in MASLD. J Hepatol. https:\/\/doi.org\/10.1016\/j.jhep.2025.09.013","journal-title":"J Hepatol"},{"issue":"4","key":"6759_CR70","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.jhep.2020.11.024","volume":"74","author":"C Bianco","year":"2021","unstructured":"Bianco C, Jamialahmadi O, Pelusi S et al (2021) Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores. J Hepatol 74(4):775\u2013782. https:\/\/doi.org\/10.1016\/j.jhep.2020.11.024","journal-title":"J Hepatol"},{"issue":"11","key":"6759_CR71","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1007\/s00535-024-02144-5","volume":"59","author":"C Yu","year":"2024","unstructured":"Yu C, Tang Y, Liu M et al (2024) The risk stratification and predictive performance of a new combined polygenic risk score for hepatocellular carcinoma. J Gastroenterol 59(11):1011\u20131020. https:\/\/doi.org\/10.1007\/s00535-024-02144-5","journal-title":"J Gastroenterol"},{"issue":"3","key":"6759_CR72","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/apt.18099","volume":"60","author":"L Bridi","year":"2024","unstructured":"Bridi L, Agrawal S, Tesfai K et al (2024) The impact of genetic risk on the prevalence of advanced fibrosis and cirrhosis in prospectively assessed patients with type 2 diabetes. Aliment Pharmacol Ther 60(3):369\u2013377. https:\/\/doi.org\/10.1111\/apt.18099","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"6759_CR73","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s00125-017-4210-x","volume":"60","author":"MI McCarthy","year":"2017","unstructured":"McCarthy MI (2017) Painting a new picture of personalised medicine for diabetes. Diabetologia 60(5):793\u2013799. https:\/\/doi.org\/10.1007\/s00125-017-4210-x","journal-title":"Diabetologia"},{"key":"6759_CR74","doi-asserted-by":"publisher","first-page":"1605721","DOI":"10.3389\/fgene.2025.1605721","volume":"16","author":"EP Sorokin","year":"2025","unstructured":"Sorokin EP, Cule M, Thanaj M et al (2025) Genetic subtypes of type 2 diabetes are distinguished through the lens of abdominal MRI. Front Genet 16:1605721. https:\/\/doi.org\/10.3389\/fgene.2025.1605721","journal-title":"Front Genet"},{"key":"6759_CR75","doi-asserted-by":"publisher","DOI":"10.1038\/s41431-025-01931-9","author":"E Roberts","year":"2025","unstructured":"Roberts E, Flaum N, Evans DG (2025) Clinical implementation of polygenic risk scores. Eur J Hum Genet. https:\/\/doi.org\/10.1038\/s41431-025-01931-9","journal-title":"Eur J Hum Genet"},{"issue":"2","key":"6759_CR76","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.jhep.2022.02.022","volume":"77","author":"H Innes","year":"2022","unstructured":"Innes H, Morling JR, Buch S, Hamill V, Stickel F, Guha IN (2022) Performance of routine risk scores for predicting cirrhosis-related morbidity in the community. J Hepatol 77(2):365\u2013376. https:\/\/doi.org\/10.1016\/j.jhep.2022.02.022","journal-title":"J Hepatol"},{"issue":"6","key":"6759_CR77","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1053\/j.gastro.2023.01.040","volume":"164","author":"VL Chen","year":"2023","unstructured":"Chen VL, Oliveri A, Miller MJ et al (2023) PNPLA3 genotype and diabetes identify patients with nonalcoholic fatty liver disease at high risk of incident cirrhosis. Gastroenterology 164(6):966-977.e917. https:\/\/doi.org\/10.1053\/j.gastro.2023.01.040","journal-title":"Gastroenterology"},{"issue":"1","key":"6759_CR78","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/jgh.12656","volume":"30","author":"J Shen","year":"2015","unstructured":"Shen J, Wong GL, Chan HL et al (2015) PNPLA3 gene polymorphism and response to lifestyle modification in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol 30(1):139\u2013146. https:\/\/doi.org\/10.1111\/jgh.12656","journal-title":"J Gastroenterol Hepatol"},{"issue":"5","key":"6759_CR79","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1111\/liv.15533","volume":"43","author":"J Boeckmans","year":"2023","unstructured":"Boeckmans J, Gatzios A, Schattenberg JM, Koek GH, Rodrigues RM, Vanhaecke T (2023) PNPLA3 I148M and response to treatment for hepatic steatosis: a systematic review. Liver Int 43(5):975\u2013988. https:\/\/doi.org\/10.1111\/liv.15533","journal-title":"Liver Int"},{"issue":"8","key":"6759_CR80","doi-asserted-by":"publisher","first-page":"167","DOI":"10.12998\/wjcc.v6.i8.167","volume":"6","author":"JZ Wang","year":"2018","unstructured":"Wang JZ, Cao HX, Chen JN, Pan Q (2018) PNPLA3 rs738409 underlies treatment response in nonalcoholic fatty liver disease. World J Clin Cases 6(8):167\u2013175. https:\/\/doi.org\/10.12998\/wjcc.v6.i8.167","journal-title":"World J Clin Cases"},{"issue":"3","key":"6759_CR81","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s12020-020-02470-7","volume":"70","author":"Y Chen","year":"2020","unstructured":"Chen Y, Yan X, Xu X, Yuan S, Xu F, Liang H (2020) PNPLA3 I148M is involved in the variability in anti-NAFLD response to exenatide. Endocrine 70(3):517\u2013525. https:\/\/doi.org\/10.1007\/s12020-020-02470-7","journal-title":"Endocrine"},{"issue":"6","key":"6759_CR82","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1007\/s00394-017-1499-7","volume":"57","author":"AC Kaliora","year":"2018","unstructured":"Kaliora AC, Kalafati IP, Gioxari A, Diolintzi A, Kokkinos A, Dedoussis GV (2018) A modified response of NAFLD patients with non-significant fibrosis in nutritional counseling according to GCKR rs1260326. Eur J Nutr 57(6):2227\u20132235. https:\/\/doi.org\/10.1007\/s00394-017-1499-7","journal-title":"Eur J Nutr"},{"key":"6759_CR83","doi-asserted-by":"publisher","first-page":"752","DOI":"10.3389\/fphar.2018.00752","volume":"9","author":"M Kawaguchi-Suzuki","year":"2018","unstructured":"Kawaguchi-Suzuki M, Cusi K, Bril F, Gong Y, Langaee T, Frye RF (2018) A genetic score associates with pioglitazone response in patients with non-alcoholic steatohepatitis. Front Pharmacol 9:752. https:\/\/doi.org\/10.3389\/fphar.2018.00752","journal-title":"Front Pharmacol"},{"issue":"4","key":"6759_CR84","doi-asserted-by":"publisher","first-page":"e1008629","DOI":"10.1371\/journal.pgen.1008629","volume":"16","author":"CA Emdin","year":"2020","unstructured":"Emdin CA, Haas ME, Khera AV et al (2020) A missense variant in Mitochondrial Amidoxime Reducing Component 1 gene and protection against liver disease. PLoS Genet 16(4):e1008629. https:\/\/doi.org\/10.1371\/journal.pgen.1008629","journal-title":"PLoS Genet"},{"issue":"1","key":"6759_CR85","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jhep.2025.06.021","volume":"84","author":"Q Zeng","year":"2026","unstructured":"Zeng Q, Patel S, Wang X et al (2026) Somatic loss-of-function mutations in CIDEB reduce hepatic steatosis by increasing lipolysis and fatty acid oxidation. J Hepatol 84(1):35\u201350. https:\/\/doi.org\/10.1016\/j.jhep.2025.06.021","journal-title":"J Hepatol"},{"key":"6759_CR86","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.molmet.2019.01.013","volume":"22","author":"D Lind\u00e9n","year":"2019","unstructured":"Lind\u00e9n D, Ahnmark A, Pingitore P et al (2019) Pnpla3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis and fibrosis in Pnpla3 I148M knock-in mice. Mol Metab 22:49\u201361. https:\/\/doi.org\/10.1016\/j.molmet.2019.01.013","journal-title":"Mol Metab"},{"issue":"1","key":"6759_CR87","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jhep.2024.12.046","volume":"83","author":"J Armisen","year":"2025","unstructured":"Armisen J, Rauschecker M, Sarv J et al (2025) AZD2693, a PNPLA3 antisense oligonucleotide, for the treatment of MASH in 148M homozygous participants: two randomized phase I trials. J Hepatol 83(1):31\u201342. https:\/\/doi.org\/10.1016\/j.jhep.2024.12.046","journal-title":"J Hepatol"},{"issue":"11","key":"6759_CR88","doi-asserted-by":"publisher","first-page":"11127","DOI":"10.1021\/acs.jmedchem.5c00119","volume":"68","author":"L Chen","year":"2025","unstructured":"Chen L, Liang Z, Mao J et al (2025) Discovery of highly potent, selective, and liver-targeting HSD17B13 inhibitor with robust in vivo Anti-MASH activity. J Med Chem 68(11):11127\u201311148. https:\/\/doi.org\/10.1021\/acs.jmedchem.5c00119","journal-title":"J Med Chem"},{"issue":"4","key":"6759_CR89","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.jhep.2025.05.031","volume":"83","author":"AJ Sanyal","year":"2025","unstructured":"Sanyal AJ, Taubel J, Badri P et al (2025) Phase I randomized double-blind study of an RNA interference therapeutic targeting HSD17B13 for metabolic dysfunction-associated steatohepatitis. J Hepatol 83(4):838\u2013848. https:\/\/doi.org\/10.1016\/j.jhep.2025.05.031","journal-title":"J Hepatol"},{"issue":"25","key":"6759_CR90","doi-asserted-by":"publisher","first-page":"2937","DOI":"10.3748\/wjg.v28.i25.2937","volume":"28","author":"ZY Li","year":"2022","unstructured":"Li ZY, Wu G, Qiu C et al (2022) Mechanism and therapeutic strategy of hepatic TM6SF2-deficient non-alcoholic fatty liver diseases via in vivo and in vitro experiments. World J Gastroenterol 28(25):2937\u20132954. https:\/\/doi.org\/10.3748\/wjg.v28.i25.2937","journal-title":"World J Gastroenterol"},{"issue":"4","key":"6759_CR91","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s42255-023-00775-1","volume":"5","author":"O Govaere","year":"2023","unstructured":"Govaere O, Hasoon M, Alexander L et al (2023) A proteo-transcriptomic map of non-alcoholic fatty liver disease signatures. Nat Metab 5(4):572\u2013578. https:\/\/doi.org\/10.1038\/s42255-023-00775-1","journal-title":"Nat Metab"},{"issue":"12","key":"6759_CR92","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.1038\/s41588-025-02407-8","volume":"57","author":"Z Li","year":"2025","unstructured":"Li Z, Luo G, Gan C et al (2025) Spatially resolved multi-omics of human metabolic dysfunction-associated steatotic liver disease. Nat Genet 57(12):3112\u20133125. https:\/\/doi.org\/10.1038\/s41588-025-02407-8","journal-title":"Nat Genet"},{"issue":"15","key":"6759_CR93","doi-asserted-by":"publisher","first-page":"5502","DOI":"10.3390\/jcm14155502","volume":"14","author":"B Vermillion","year":"2025","unstructured":"Vermillion B, Mao Y (2025) Metabolic dysfunction-associated steatotic liver disease in people with type 1 diabetes. J Clin Med 14(15):5502. https:\/\/doi.org\/10.3390\/jcm14155502","journal-title":"J Clin Med"},{"issue":"1","key":"6759_CR94","doi-asserted-by":"publisher","first-page":"4847","DOI":"10.1038\/s41467-024-49224-x","volume":"15","author":"SM Johnson","year":"2024","unstructured":"Johnson SM, Bao H, McMahon CE et al (2024) PNPLA3 is a triglyceride lipase that mobilizes polyunsaturated fatty acids to facilitate hepatic secretion of large-sized very low-density lipoprotein. Nat Commun 15(1):4847. https:\/\/doi.org\/10.1038\/s41467-024-49224-x","journal-title":"Nat Commun"},{"issue":"44","key":"6759_CR95","doi-asserted-by":"publisher","first-page":"45685","DOI":"10.1074\/jbc.M404255200","volume":"279","author":"H Hirokane","year":"2004","unstructured":"Hirokane H, Nakahara M, Tachibana S, Shimizu M, Sato R (2004) Bile acid reduces the secretion of very low density lipoprotein by repressing microsomal triglyceride transfer protein gene expression mediated by hepatocyte nuclear factor-4. J Biol Chem 279(44):45685\u201345692. https:\/\/doi.org\/10.1074\/jbc.M404255200","journal-title":"J Biol Chem"},{"key":"6759_CR96","doi-asserted-by":"publisher","first-page":"104809","DOI":"10.1016\/j.nbd.2020.104809","volume":"138","author":"AB Mart\u00ednez-Mart\u00ednez","year":"2020","unstructured":"Mart\u00ednez-Mart\u00ednez AB, Torres-Perez E, Devanney N, Del Moral R, Johnson LA, Arbones-Mainar JM (2020) Beyond the CNS: the many peripheral roles of APOE. Neurobiol Dis 138:104809. https:\/\/doi.org\/10.1016\/j.nbd.2020.104809","journal-title":"Neurobiol Dis"},{"issue":"1","key":"6759_CR97","doi-asserted-by":"publisher","first-page":"9320","DOI":"10.1038\/s41598-023-36512-7","volume":"13","author":"S Soubeyrand","year":"2023","unstructured":"Soubeyrand S, Lau P, McPherson R (2023) Regulation of TRIB1 abundance in hepatocyte models in response to proteasome inhibition. Sci Rep 13(1):9320. https:\/\/doi.org\/10.1038\/s41598-023-36512-7","journal-title":"Sci Rep"},{"issue":"4","key":"6759_CR98","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1055\/s-0033-1358523","volume":"33","author":"X Xu","year":"2013","unstructured":"Xu X, So JS, Park JG, Lee AH (2013) Transcriptional control of hepatic lipid metabolism by SREBP and ChREBP. Semin Liver Dis 33(4):301\u2013311. https:\/\/doi.org\/10.1055\/s-0033-1358523","journal-title":"Semin Liver Dis"},{"issue":"2","key":"6759_CR99","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.jcmgh.2023.10.002","volume":"17","author":"KR Smith","year":"2024","unstructured":"Smith KR, Wang W, Miller MR et al (2024) GPAT1 deficiency in mice modulates NASH progression in a model-dependent manner. Cell Mol Gastroenterol Hepatol 17(2):279\u2013291. https:\/\/doi.org\/10.1016\/j.jcmgh.2023.10.002","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"1","key":"6759_CR100","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jhep.2020.08.027","volume":"74","author":"K Teo","year":"2021","unstructured":"Teo K, Abeysekera KWM, Adams L et al (2021) rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: a meta-analysis. J Hepatol 74(1):20\u201330. https:\/\/doi.org\/10.1016\/j.jhep.2020.08.027","journal-title":"J Hepatol"},{"issue":"4","key":"6759_CR101","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.bbrc.2011.02.105","volume":"406","author":"M Shigekawa","year":"2011","unstructured":"Shigekawa M, Takehara T, Kodama T et al (2011) Involvement of STAT3-regulated hepatic soluble factors in attenuation of stellate cell activity and liver fibrogenesis in mice. Biochem Biophys Res Commun 406(4):614\u2013620. https:\/\/doi.org\/10.1016\/j.bbrc.2011.02.105","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"6759_CR102","doi-asserted-by":"publisher","first-page":"e175328","DOI":"10.1172\/jci.insight.175328","volume":"9","author":"A Hernandez-Ono","year":"2024","unstructured":"Hernandez-Ono A, Zhao YP, Murray JW et al (2024) Dynamic regulation of hepatic lipid metabolism by torsinA and its activators. JCI Insight 9(3):e175328. https:\/\/doi.org\/10.1172\/jci.insight.175328","journal-title":"JCI Insight"},{"issue":"47","key":"6759_CR103","doi-asserted-by":"publisher","first-page":"11958","DOI":"10.1073\/pnas.1808576115","volume":"115","author":"C Kubitza","year":"2018","unstructured":"Kubitza C, Bittner F, Ginsel C, Havemeyer A, Clement B, Scheidig AJ (2018) Crystal structure of human mARC1 reveals its exceptional position among eukaryotic molybdenum enzymes. Proc Natl Acad Sci U S A 115(47):11958\u201311963. https:\/\/doi.org\/10.1073\/pnas.1808576115","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"6759_CR104","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1002\/hep.21023","volume":"43","author":"E Zintzaras","year":"2006","unstructured":"Zintzaras E, Stefanidis I, Santos M, Vidal F (2006) Do alcohol-metabolizing enzyme gene polymorphisms increase the risk of alcoholism and alcoholic liver disease? Hepatology 43(2):352\u2013361. https:\/\/doi.org\/10.1002\/hep.21023","journal-title":"Hepatology"},{"issue":"4","key":"6759_CR105","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.jhep.2021.11.022","volume":"76","author":"M Fromme","year":"2022","unstructured":"Fromme M, Schneider CV, Trautwein C, Brunetti-Pierri N, Strnad P (2022) Alpha-1 antitrypsin deficiency: a re-surfacing adult liver disorder. J Hepatol 76(4):946\u2013958. https:\/\/doi.org\/10.1016\/j.jhep.2021.11.022","journal-title":"J Hepatol"},{"issue":"5","key":"6759_CR106","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/s42255-023-00807-w","volume":"5","author":"V Glunk","year":"2023","unstructured":"Glunk V, Laber S, Sinnott-Armstrong N et al (2023) A non-coding variant linked to metabolic obesity with normal weight affects actin remodelling in subcutaneous adipocytes. Nat Metab 5(5):861\u2013879. https:\/\/doi.org\/10.1038\/s42255-023-00807-w","journal-title":"Nat Metab"},{"issue":"6","key":"6759_CR107","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1194\/jlr.M090928","volume":"60","author":"A Taxiarchis","year":"2019","unstructured":"Taxiarchis A, Mahdessian H, Silveira A, Fisher RM, Van\u2019t Hooft FM (2019) PNPLA2 influences secretion of triglyceride-rich lipoproteins by human hepatoma cells. J Lipid Res 60(6):1069\u20131077. https:\/\/doi.org\/10.1194\/jlr.M090928","journal-title":"J Lipid Res"},{"issue":"3","key":"6759_CR108","doi-asserted-by":"publisher","first-page":"653","DOI":"10.2337\/dbi20-0006","volume":"70","author":"A Cui","year":"2021","unstructured":"Cui A, Ding D, Li Y (2021) Regulation of hepatic metabolism and cell growth by the ATF\/CREB family of transcription factors. Diabetes 70(3):653\u2013664. https:\/\/doi.org\/10.2337\/dbi20-0006","journal-title":"Diabetes"},{"issue":"1","key":"6759_CR109","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.gendis.2021.01.005","volume":"9","author":"Z Yang","year":"2022","unstructured":"Yang Z, Yu GL, Zhu X, Peng TH, Lv YC (2022) Critical roles of FTO-mediated mRNA m6A demethylation in regulating adipogenesis and lipid metabolism: Implications in lipid metabolic disorders. Genes Dis 9(1):51\u201361. https:\/\/doi.org\/10.1016\/j.gendis.2021.01.005","journal-title":"Genes Dis"},{"issue":"15","key":"6759_CR110","doi-asserted-by":"publisher","first-page":"11913","DOI":"10.3390\/ijms241511913","volume":"24","author":"M Rumpf","year":"2023","unstructured":"Rumpf M, Pautz S, Drebes B, Herberg FW, M\u00fcller HJ (2023) Microtubule-Associated Serine\/Threonine (MAST) kinases in development and disease. Int J Mol Sci 24(15):11913. https:\/\/doi.org\/10.3390\/ijms241511913","journal-title":"Int J Mol Sci"},{"issue":"11","key":"6759_CR111","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1038\/s41588-018-0248-z","volume":"50","author":"O Canela-Xandri","year":"2018","unstructured":"Canela-Xandri O, Rawlik K, Tenesa A (2018) An atlas of genetic associations in UK Biobank. Nat Genet 50(11):1593\u20131599. https:\/\/doi.org\/10.1038\/s41588-018-0248-z","journal-title":"Nat Genet"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-026-06759-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-026-06759-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-026-06759-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:39:22Z","timestamp":1790771962000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00125-026-06759-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":111,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["6759"],"URL":"https:\/\/doi.org\/10.1007\/s00125-026-06759-6","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"assertion":[{"value":"18 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"HY is supported by Diabetes UK (grant 23\/0006598).","order":1,"name":"Ethics","label":"Funding","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.","order":2,"name":"Ethics","label":"Authors\u2019 relationships and activities","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Both authors were responsible for drafting different sections of the article and for reviewing the whole article critically for important intellectual content. Both authors approved the version to be published.","order":3,"name":"Ethics","label":"Contribution statement","group":{"name":"EthicsHeading","label":"Ethics"}}]}}